Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Ranbaxy Obtains Approval To Market Ran-Rosuvastatin In Canada - Quick Facts

Ranbaxy Pharmaceuticals Canada Inc. or RPCI, a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced that RPCI has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. Rosuvastatin is a HMG-COA Reductase Inhibitor (cholesterol-lowering medication). Brand sales of Crestorin Canada were $742.2 million.

"The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. We anticipate making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies are available to meet market demand," said Paul Drake, President and General Manager of RPCI.

Click here to receive FREE breaking news email alerts for RANBAXY LABS LTD and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Two federal appeals courts have issued contradictory rulings over the federal government's ability to provide subsidies under Obamacare, suggesting that the future of President Barack Obama's healthcare law could once again end up in the hands of the U.S. Supreme Court. After ending the previous session modestly lower, stocks have shown a strong move back to the upside during trading on Tuesday. With the upward move on the day, the S&P 500 has reached a new record intraday high. A majority of Americans believe Israel is justified in taking military action against Gaza, according to the results of a new CNN/ORC International survey, although opinions about the amount of military force the Israelis have used are more divided.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.